journal article·2025-12Open access

FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression

Hongxu Nie, Hengjie Xu, Sheng Yang, Chuanxin Tian, Tuo Wang, Chi Jin, Zhihao Chen, Xiaowei Wang, Junwei Tang, Yifei Feng, Yueming Sun

Advanced Science· Volume 12· Issue 47

Abstract

Abstract Emerging evidence highlights the role of SCF E3 ligases, consisting of SKP1, cullin‐1, and F‐box proteins, in cancer biology by regulating the ubiquitination and degradation of key proteins. This study identifies F‐box only protein 44 (FBXO44) as an oncogene in colorectal cancer (CRC). FBXO44 is upregulated in CRC patients and correlates with poor prognosis. Knockdown of FBXO44 inhibits CRC cell proliferation and organoid growth, as well as xenograft tumor growth and AOM/DSS‐induced intestinal tumorigenesis. Conversely, FBXO44 overexpression accelerates tumor growth in vitro and in vivo. Mechanistically, FBXO44 targets Forkhead box protein P1 (FOXP1) for degradation. Aurora kinase A (AURKA) phosphorylates FOXP1 at Ser440, enhancing FBXO44 binding, leading to K48‐linked ubiquitination at K377 and proteasomal degradation. This degradation relieves FOXP1 repression of Cyclin E2, promoting CRC cell proliferation. In summary, FBXO44 is an oncogene that promotes CRC tumorigenesis by degrading FOXP1 and upregulating Cyclin E2, offering a potential therapeutic target for CRC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ubiquitin and proteasome pathways · NF-κB Signaling Pathways · Protein Tyrosine Phosphatases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery Colorectal Institute of Nanjing Medical University The First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China

Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine Nanjing 210029 China

Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing 210029 China

Department of General Surgery The Third Affiliated Hospital of Nanjing Medical University Changzhou 213100 China

Department of General Surgery, Qilu Hospital Shandong University Jinan 250012 China

Funding

Basic Research Program of Jiangsu Province · National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.3322/caac.2182010.3322/caac.21820 ↗
2. 10.1016/j.canlet.2021.09.03410.1016/j.canlet.2021.09.034 ↗
3. 10.3322/caac.2177210.3322/caac.21772 ↗
4. 10.1016/j.bbcan.2022.18873510.1016/j.bbcan.2022.188735 ↗
5. 10.1038/s41467-023-35795-810.1038/s41467-023-35795-8 ↗
6. 10.1016/j.bbcan.2024.18909910.1016/j.bbcan.2024.189099 ↗
7. 10.1038/nrc370010.1038/nrc3700 ↗
8. 10.1016/j.bbcan.2023.18903510.1016/j.bbcan.2023.189035 ↗
9. 10.1016/j.drup.2019.10067310.1016/j.drup.2019.100673 ↗
10. 10.1016/j.semcancer.2015.09.01510.1016/j.semcancer.2015.09.015 ↗
11. 10.1074/jbc.M112.40710610.1074/jbc.M112.407106 ↗
12. 10.1038/nrm154710.1038/nrm1547 ↗
13. 10.1074/jbc.M70950820010.1074/jbc.M709508200 ↗
14. 10.1371/journal.pone.012358110.1371/journal.pone.0123581 ↗
15. 10.1124/molpharm.120.00006110.1124/molpharm.120.000061 ↗
16. 10.1016/j.apsb.2023.07.01410.1016/j.apsb.2023.07.014 ↗
17. 10.1371/journal.pone.028079410.1371/journal.pone.0280794 ↗
18. 10.1517/14728222.11.7.95510.1517/14728222.11.7.955 ↗
19. 10.1186/s12943-019-1110-310.1186/s12943-019-1110-3 ↗
20. 10.1158/1078-0432.1065.11.310.1158/1078-0432.1065.11.3 ↗
21. 10.1200/JCO.2006.05.615010.1200/JCO.2006.05.6150 ↗
22. 10.1038/modpathol.380065010.1038/modpathol.3800650 ↗
23. 10.1016/j.ymthe.2019.03.00610.1016/j.ymthe.2019.03.006 ↗
24. 10.1038/s41419-020-03007-610.1038/s41419-020-03007-6 ↗
25. 10.1038/oncsis.2016.8010.1038/oncsis.2016.80 ↗
26. Shen J. Z. · Cell · 2021 · 184
27. 10.1038/416703a10.1038/416703a ↗
28. 10.1038/nrc239610.1038/nrc2396 ↗
29. 10.1016/j.cell.2008.07.03910.1016/j.cell.2008.07.039 ↗
30. 10.1073/pnas.040277010110.1073/pnas.0402770101 ↗
31. 10.1038/sj.emboj.760021710.1038/sj.emboj.7600217 ↗
32. Park S. · Exp. Mol. Med. · 2024 · 56
33. 10.1016/j.celrep.2019.12.03210.1016/j.celrep.2019.12.032 ↗
34. Liu J. · J Immunother Cancer · 2022 · 10
35. 10.1038/s41418-021-00739-610.1038/s41418-021-00739-6 ↗
36. 10.1158/1541-7786.MCR-17-043210.1158/1541-7786.MCR-17-0432 ↗
37. 10.1038/s41467-019-09289-510.1038/s41467-019-09289-5 ↗
38. 10.1038/s41467-022-34747-y10.1038/s41467-022-34747-y ↗
39. 10.1038/s41392-023-01405-810.1038/s41392-023-01405-8 ↗
40. 10.1038/ng127910.1038/ng1279 ↗
41. 10.1002/ctm2.56510.1002/ctm2.565 ↗
42. 10.1002/ctm2.21110.1002/ctm2.211 ↗
43. 10.1038/s41388-022-02581-710.1038/s41388-022-02581-7 ↗
44. 10.1111/cpr.1250510.1111/cpr.12505 ↗
45. 10.1186/s13046-021-02074-710.1186/s13046-021-02074-7 ↗
46. 10.1186/s13046-022-02551-710.1186/s13046-022-02551-7 ↗
47. 10.1038/s41419-022-05240-710.1038/s41419-022-05240-7 ↗